

Perspective

Cite this article: Drost RMWA, Paulus ATG, Evers SMAA (2020). Five pillars for societal perspective. *International Journal of Technology Assessment in Health Care* 36, 72–74. <https://doi.org/10.1017/S026646232000001X>

Received: 5 November 2019

Revised: 18 December 2019

Accepted: 29 December 2019

First published online: 31 January 2020

Keywords:

Economic evaluation; Economic analysis; Costs; Societal perspective; Intersectoral costs




Author for correspondence:

Ruben Drost,

E-mail: r.drost@maastrichtuniversity.nl

© Cambridge University Press 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Five pillars for societal perspective

Ruben M. W. A. Drost¹ , Aggie T. G. Paulus¹  and Silvia M. A. A. Evers^{1,2} 

¹Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Duboisdomein 30, 6229 GT, Maastricht, The Netherlands and ²Trimbos, Netherlands Institute of Mental Health and Addiction, Da Costakade 45, 3521 VS, Utrecht, The Netherlands

In economic evaluation, the healthcare perspective has gradually given way to use of the societal perspective, as this perspective is often advocated for support in making optimal societal decisions. In practice, economic evaluations conducted from the societal perspective ignore, fail to measure and/or fail to monetize many of the costs that fall outside of the healthcare sector. To limit bias and increase decision-supportive power, researchers could strengthen their evaluations by adhering to a few basic principles. Five “pillars for the societal perspective” are proposed. First, who bears the cost and who does not is irrelevant. Second, it is imperative to consider including costs for sectors outside the healthcare sector. Third, both high frequent costs and costs with high unit prices should be considered. Fourth, double counting should be avoided. And fifth, researchers should reflect on choices related to costs, i.e. cost omission and problems with identifying, measuring, and valuing costs.

Why the Societal Perspective?

One of the major problems in health economic evaluation is adequately assessing the societal costs of an intervention. The core of the solution is the choice of perspective. The healthcare perspective has gradually given way to use of the societal perspective, as this perspective is often advocated for support in making optimal societal decisions (1–3). With welfare economics as its underlying theoretical framework, adopting a societal perspective facilitates policies aimed at maximizing the welfare gains to society (2;4). From this perspective, to optimize the decision-supportive power of these evaluations, all societal costs resulting from the intervention under analysis should be incorporated, regardless of who the payer is (5). In practice, economic evaluations conducted from the societal perspective ignore, fail to measure and/or fail to monetize many of these costs (6–8). Illustrative earlier reviews on paediatric urology (9) and depression (10) discuss this issue with regard to the variability in the operationalization of this perspective. Furthermore, research shows that some authors use the denominator “societal perspective” yet include only those costs falling within the healthcare sector (6). As a result, many evaluations in which this perspective has been adopted have limited supportive power for decision making.

Problems with Operationalizing the Societal Perspective

The underlying reasoning and the methodological choices which lie at the foundation of this limitation remain hidden and are likely to vary among researchers. Such choices may have been made either unintentionally or deliberately, both in conducting and reporting evaluations, and costs might have been left out of the equation due to the lack of knowledge, to misconception of what the societal perspective is, and to poor operationalization of it. However, even those knowledgeable with regard to the operationalization of this perspective face challenges in producing the most optimal assessment, and may produce evaluations that are too narrow in scope. This is primarily because currently available methods for identifying, measuring, and valuing costs are limited with regard to the societal perspective. Research on revealed preference methods for valuing costs outside the healthcare sector is restricted mainly to productivity costs (the human capital method, the friction cost method) and costs of informal care (the opportunity cost method, the proxy good method) (11–14), while research into measuring and valuing costs in other sectors, for example the educational and criminal justice sectors, lags behind. Several costing studies on mental illness and substance use show that costs in these sectors can be substantial (15–19). For such health domains in particular, leaving these costs out of the equation can lead to biased economic evaluation results.

A second practical issue is that researchers are also dealing with limited time and resources, and therefore face trade-offs in selecting and measuring costs. Consequently, evaluations vary not only in terms of quality, but also in terms of costs selection, and this negatively affects their comparability. However, even within the methodological constraints, researchers should strive to produce high-quality evaluations which are decision supportive. Ultimately, the decision-supportive power of an evaluation depends, among other factors, on the degree to which

costs are reflected in the evaluation. The question remains whether, in general, researchers actively strive to produce the most optimal cost assessment possible.

Principles for Using Societal Perspective

To limit bias and increase decision-supportive power, researchers adopting the societal perspective could strengthen their evaluations by adhering to a few basic principles. The following five “pillars for the societal perspective” are proposed; these will be particularly helpful to those with limited experience in conducting health economic evaluations. First, who bears the cost and who does not is irrelevant. If there is a mechanism for others to be affected, researchers should strive to measure and value the spill-over costs for others than the primary affected individual, such as relatives, insurers, and others. Second, when adopting a societal perspective, as opposed to the healthcare perspective, it is imperative to consider including costs for sectors outside the healthcare sector. This could mean looking beyond labor productivity and informal care. For example, depending on the intervention, researchers could consider assessing costs within other sectors, such as the educational and criminal justice sectors (1;20). Third, both high frequent costs relevant to the evaluation and costs with high unit prices, outside the healthcare sector as well as within it could be measured and included in analyses. Any uncertainty related to ex ante decisions in cost selection should be addressed by consulting literature, e.g. exemplary costing studies, or experts in the contextual field of research, i.e. disease type, type of intervention, target population, et cetera. Any uncertainty related to the causality between the intervention and costs could be addressed by conducting appropriate additional scenario or sensitivity analyses. Fourth, when a societal perspective is adopted, researchers might need to include broader outcomes besides clinical outcome measures or generic health-related quality of life measures such as the quality adjusted life year (QALY). In an economic analysis, researchers should value only costs that have not been included as an outcome. For example, lost days of productivity at work should not be valued if this is the main outcome of the cost-effectiveness analysis. Irrespective of the chosen perspective, double counting by including items both in the input side of the evaluation, i.e. costing side, and the output side, i.e. the QALY or other outcome measures, should be avoided at all times (21). Finally, like for other methodological choices, researchers should reflect and report on choices related to costs, i.e. cost omission and any problems with identifying, measuring, and valuing costs. Although guidelines for reporting economic evaluations prescribe that methodological limitations should be discussed (22), there is little reflection on choices about costs as a methodological strength or limitation (6).

Conclusion

Worldwide, still many health economic guidelines have not adopted the societal perspective as the leading perspective (23). Furthermore, given that many societal decisions are made within the limits of budget silos, estimating the return of investment for a payer or the healthcare sector itself might often be prioritized over estimating the cost savings for other sectors. Consequently, despite the many arguments for the use of the societal perspective (1–3), in practice the choice for the more methodologically feasible narrow perspective is still often favored. Yet, taking societal welfare, and not practical feasibility as a starting point, striving

towards a more complete picture of the societal impact of interventions needs to be supported. The societal perspective in economic evaluations is important because of its higher decision-supportive power to optimize resource allocation. HTA- and health economics researchers should, therefore, strive to develop methods for bringing economic evaluations as close to a true societal perspective as possible. This includes developing methods for including non-healthcare costs and outcomes in the equation, instead of listing these separately. Furthermore, for each separate economic evaluation, authors should consider whether the use of the term “societal” can be justified (1). For many economic evaluations, using terminology such as “healthcare”, “payer”, or other proposed terms such as “restricted societal”, “limited societal”, or “health systems” (24), might be more appropriate.

Contributor and Guarantor Information

The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Silvia Evers had the idea for the editorial. Ruben Drost took the lead in writing the article. All authors made substantial contributions to the conception and design of the work, the drafting of the work, and revising it critically for important intellectual content. All gave final approval of the version to be published in International Journal of Technology Assessment in Health Care. Ruben Drost is the guarantor (the contributor who accepts full responsibility for the finished article, had access to any data, and controlled the decision to publish).

Copyright/License for Publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide license to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to (i) publish, reproduce, distribute, display, and store the Contribution, (ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, (iii) create any other derivative work(s) based on the Contribution, (iv) to exploit all subsidiary rights in the Contribution, (v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located, and (vi) license any third party to do any or all of the above.

Conflict Interest. We have read and understood International Journal of Technology Assessment in Health Care policy on declaration of interests and declare that we have no competing interests.

Ethical Statement. No patients and/or members of the public were involved in the creation of the article.

References

1. Walker S, Griffin S, Asaria M *et al.* (2019) Striving for a societal perspective: A framework for economic evaluations when costs and effects fall on multiple sectors and decision makers. *Appl Health Econ Health Policy* 17(5), 577-590.
2. Byford S, Raftery J (1998) Perspectives in economic evaluation. *Br Med J*. 316(7143), 1529-1530.
3. Jonsson B (2009) Ten arguments for a societal perspective in the economic evaluation of medical innovations. *Eur J Health Econ* 10(4), 357-359.

4. **Brouwer WB, Culyer AJ, van Exel NJ *et al.*** (2008) Welfarism vs. Extra-welfarism. *J Health Econ* **27**(2), 325-338.
5. **Gold MR, Siegel JE, Russell LB *et al.*** (1996) *Cost-effectiveness in health and medicine*. New York: Oxford University Press.
6. **Drost RMWA, van der Putten IM, Ruwaard D *et al.*** (2017) Conceptualizations of the societal perspective within economic evaluations: A systematic review. *Int J Technol Assess Health Care* **33**(2), 251-260.
7. **Neumann PJ** (2009) Costing and perspective in published cost-effectiveness analysis. *Med Care* **47**(7 Suppl 1), S28-S32.
8. **Sanders GD, Neumann PJ, Basu A *et al.*** (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. *JAMA* **316**(10), 1093-1103.
9. **Kokorowski PJ, Routh JC, Nelson CP** (2013) Quality assessment of economic analyses in pediatric urology. *Urology* **81**(2), 263-267.
10. **Brettschneider C, Djadran H, Harter M *et al.*** (2015) Cost-utility analyses of cognitive-behavioural therapy of depression: A systematic review. *Psychother Psychosom* **84**(1), 6-21.
11. **Weisbrod BA** (1961) *Economics of public health: Measuring the economic impact of diseases*. Philadelphia: University of Pennsylvania Press.
12. **Koopmanschap MA, Rutten FF, van Ineveld BM *et al.*** (1995) The friction cost method for measuring indirect costs of disease. *J Health Econ* **14**(2), 171-189.
13. **Koopmanschap MA, van Exel JN, van den Berg B *et al.*** (2008) An overview of methods and applications to value informal care in economic evaluations of healthcare. *Pharmacoeconomics* **26**(4), 269-280.
14. **van den Berg B, Brouwer WB, Koopmanschap MA** (2004) Economic valuation of informal care. An overview of methods and applications. *Eur J Health Econ* **5**(1), 36-45.
15. **Knapp M, Romeo R, Beecham J** (2009) Economic cost of autism in the UK. *Autism* **13**(3): 317-336.
16. **Rice DP, Kelman S, Miller LS** (1991) Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. *Public Health Rep* **106**(3), 280-292.
17. **Swanson JW, Frisman LK, Robertson AG *et al.*** (2013) Costs of criminal justice involvement among persons with serious mental illness in connecticut. *Psychiatr Serv* **64**(7), 630-637.
18. **Le HH, Hodgkins P, Postma MJ *et al.*** (2014) Economic impact of childhood/adolescent ADHD in a European setting: The Netherlands as a reference case. *Eur Child Adolesc Psychiatry* **23**(7), 587-598.
19. **Mark TL, Woody GE, Juday T *et al.*** (2001) The economic costs of heroin addiction in the United States. *Drug Alcohol Depend* **61**(2), 195-206.
20. **Drost RMWA, Paulus ATG, Ruwaard D *et al.*** (2017) Valuing intersectoral costs and benefits of interventions in the healthcare sector: Methods for obtaining unit prices. *Expert Rev Pharmacoecon Outcomes Res* **17**(1), 77-84.
21. **Johannesson M.** (1997) Avoiding double-counting in pharmacoeconomic studies. *Pharmacoeconomics* **11**(5), 385-388.
22. **Husereau D, Drummond M, Petrou S *et al.*** (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. *Br Med J*. **346**, f1049.
23. **International Society for Pharmacoeconomics and Outcomes Research (ISPOR)** (2019) Pharmacoeconomic Guidelines Comparative Table. Available at: <https://tools.ispor.org/peguidelines/>. Accessed 2019.
24. **Garrison LP, Jr., Mansley EC, Abbott TA, 3rd *et al.*** (2010) Good research practices for measuring drug costs in cost-effectiveness analyses: A societal perspective: the ISPOR Drug Cost Task Force report-Part II. *Value Health* **13**(1), 8-13.